10 Biggest Losers in Cathie Wood’s Latest Portfolio
In this article, we discuss the 10 biggest losers in Cathie Wood's latest portfolio.
Intellia Therapeutics Inc. (NTLA)
Get Email AlertsHedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 8,981,029 | $652,651 | +14% | 2.72% |
| 2. | Viking Global Andreas Halvorsen | 2,468,760 | $179,405 | +57% | 0.72% |
| 3. | Himension Capital Jay Chen | 744,160 | $54,078 | +27% | 5.78% |
| 4. | Millennium Management Israel Englander | 500,266 | $36,354 | +4611% | 0.01% |
| 5. | Citadel Investment Group Ken Griffin | 486,433 | $35,349 | +136% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.50 | 4,250 | Officer | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | Officer | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | Director | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | Director | 2,603,646 | 2016-05-11 | Filing | |
| $18.00 | 300,000 | Large Shareholder | 790,527 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $112.26 | 2,493 | Officer, Director | 724,660 | 2022-01-01 | Filing | |
| $112.25 | 1,148 | Officer | 4,815 | 2022-01-01 | Filing | |
| $112.24 | 1,051 | Officer | 10,922 | 2022-01-01 | Filing | |
| $112.24 | 1,013 | Officer | 2,049 | 2022-01-01 | Filing | |
| $135.34 | 200 | Officer | 8,714 | 2021-11-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 319,404 | $23,211,089 | 0% | |
| 2. | 59,941 | $4,355,912 | 0% | |
| 3. | 6,391,940 | $464,502 | 0.01% | |
| 4. | 5,601,739 | $407,079 | 0.01% | |
| 5. | 2,794,925 | $203,108 | 0.01% |
News See All
Cathie Wood’s 10 Stock Picks for the Next 5 Years
In this article, we discuss Cathie Wood's 10 stock picks for the next 5 years.
5 Genomics Stocks in Cathie Wood’s Portfolio That Are Underperforming
In this article, we discuss 5 genomics stocks in Cathie Wood’s portfolio that are underperforming.
Did Hedge Funds Catch A Break With Intellia Therapeutics, Inc. (NTLA)?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.
5 Best Genomics Stocks to Buy Now
CRISPR Therapeutics AG (NASDAQ:CRSP) is a Swiss-American biotech company that is home to the CRISPR/Cas9 gene-editing technology that is working on treating cancer, diabetes, hemoglobinopathies, and other...
Hedge Funds Are Cashing Out Of Intellia Therapeutics, Inc. (NTLA)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
10 Growth Stocks to Buy According to Jay Chen’s Himension Capital
In this article article, we reviewed Jay Chen’s investment philosophy and portfolio management strategies. We also examined 10 growth stocks to buy according to Jay Chen’s Himension Capital.
5 Best Genomic Stocks to Buy Now
In this article, we will take a look at the 5 best genomic stocks to buy now.
Hedge Funds Are Crazy About Intellia Therapeutics, Inc. (NTLA)
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their...
Is Intellia Therapeutics (NTLA) A Great Investment Pick?
Carillon Tower Advisers, an investment management firm, published its “Carillon Eagle Small Cap Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
